Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company offers Omnipod System, which consists of self-adhesive disposable tubeless Omnipod device (the pod) that delivers insulin into the body; and Personal Diabetes Manager, a handheld wireless device, which programs the Pod.
Read More…
Industry, Sector and Symbol
Industry Surgical & medical instruments
Sub-IndustryHealth Care Equipment
SectorMedical
Phone978-600-7000
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$563.82 million
Profitability
Miscellaneous
Employees1,169
Next Earnings Date11/5/2019 (Confirmed)
OptionableOptionable
Insulet (NASDAQ:PODD) Frequently Asked Questions
What is Insulet's stock symbol?
Insulet trades on the NASDAQ under the ticker symbol "PODD."
How were Insulet's earnings last quarter?
Insulet Co. (NASDAQ:PODD) posted its quarterly earnings data on Monday, August, 5th. The medical instruments supplier reported $0.02 EPS for the quarter, missing the Thomson Reuters' consensus estimate of $0.03 by $0.01. The medical instruments supplier earned $177.10 million during the quarter, compared to analyst estimates of $163.63 million. Insulet had a net margin of 2.66% and a return on equity of 7.85%. The firm's revenue for the quarter was up 42.5% compared to the same quarter last year. During the same period in the prior year, the company posted ($0.03) earnings per share. View Insulet's Earnings History.
When is Insulet's next earnings date?
How can I listen to Insulet's earnings call?
Insulet will be holding an earnings conference call on Tuesday, November 5th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.
What guidance has Insulet issued on next quarter's earnings?
Insulet updated its third quarter 2019 earnings guidance on Monday, August, 5th. The company provided EPS guidance of for the period. The company issued revenue guidance of $174-181 million, compared to the consensus revenue estimate of $172.7 million.
What price target have analysts set for PODD?
14 brokers have issued 1 year target prices for Insulet's stock. Their forecasts range from $100.00 to $185.00. On average, they anticipate Insulet's stock price to reach $144.64 in the next twelve months. This suggests that the stock has a possible downside of 6.9%. View Analyst Price Targets for Insulet.
What is the consensus analysts' recommendation for Insulet?
14 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Insulet in the last year. There are currently 6 hold ratings and 8 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Insulet.
Has Insulet been receiving favorable news coverage?
Media stories about PODD stock have been trending neutral recently, according to InfoTrie. InfoTrie identifies negative and positive press coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Insulet earned a coverage optimism score of 0.4 on InfoTrie's scale. They also assigned press coverage about the medical instruments supplier a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the stock's share price in the immediate future. View News Stories for Insulet.
Are investors shorting Insulet?
Insulet saw a increase in short interest in September. As of September 30th, there was short interest totalling 4,710,000 shares, an increase of 13.8% from the August 30th total of 4,140,000 shares. Based on an average trading volume of 903,900 shares, the days-to-cover ratio is presently 5.2 days. Approximately 7.9% of the shares of the stock are sold short. View Insulet's Current Options Chain.
Who are some of Insulet's key competitors?
Some companies that are related to Insulet include FRESENIUS SE &/S (FSNUY), ResMed (RMD), Teleflex (TFX), DexCom (DXCM), ABIOMED (ABMD), Novocure (NVCR), Hill-Rom (HRC), Haemonetics (HAE), Integra Lifesciences (IART), Penumbra (PEN), Globus Medical (GMED), Tandem Diabetes Care (TNDM), NuVasive (NUVA), ICU Medical (ICUI) and Cantel Medical (CMD).
What other stocks do shareholders of Insulet own?
Who are Insulet's key executives?
Insulet's management team includes the folowing people:
- Ms. Shacey Petrovic, Pres, CEO & Director (Age 45)
- Mr. Charles Alpuche, Exec. VP & COO (Age 59)
- Mr. Bret Christensen, Exec. VP & Chief Commercial Officer (Age 47)
- Mr. Patrick J. Sullivan, Consultant (Age 67)
- Mr. Michael L. Levitz, Advisor (Age 45)
Who are Insulet's major shareholders?
Insulet's stock is owned by a number of of institutional and retail investors. Top institutional investors include Gradient Investments LLC (0.02%), First Hawaiian Bank (0.01%), HMS Capital Management LLC (0.00%), Cerebellum GP LLC (0.00%) and Juncture Wealth Strategies LLC (0.00%). Company insiders that own Insulet stock include Aiman Abdel-Malek, Bradley A Thomas, Charles Alpuche, David A Lemoine, David Colleran, James C Mullen, John A Fallon, Michael L Levitz, Michael P Spears, Sally Crawford and Shacey Petrovic. View Institutional Ownership Trends for Insulet.
Which major investors are buying Insulet stock?
PODD stock was acquired by a variety of institutional investors in the last quarter, including First Hawaiian Bank, Cerebellum GP LLC, Juncture Wealth Strategies LLC, Gradient Investments LLC and HMS Capital Management LLC. View Insider Buying and Selling for Insulet.
How do I buy shares of Insulet?
Shares of PODD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Insulet's stock price today?
One share of PODD stock can currently be purchased for approximately $155.42.
How big of a company is Insulet?
Insulet has a market capitalization of $9.37 billion and generates $563.82 million in revenue each year. The medical instruments supplier earns $3.29 million in net income (profit) each year or $0.05 on an earnings per share basis. Insulet employs 1,169 workers across the globe.View Additional Information About Insulet.
What is Insulet's official website?
How can I contact Insulet?
Insulet's mailing address is 100 NAGOG PARK, ACTON MA, 01720. The medical instruments supplier can be reached via phone at 978-600-7000 or via email at [email protected]
MarketBeat Community Rating for Insulet (NASDAQ PODD)
MarketBeat's community ratings are surveys of what our community members think about Insulet and other stocks. Vote "Outperform" if you believe PODD will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PODD will underperform the S&P 500 over the long term. You may vote once every thirty days.
